Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma.

Trial Details

NCT ID
NCT07749365
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • Written informed consent must be obtained before any study-related procedures.
  • Age ≥18 years, regardless of sex, with an expected survival time \>3 months.
  • Histologically confirmed diffuse large B-cell lymphoma (DLBCL).
  • Newly diagnosed patients with primary central nervous system diffuse large B-cell lymphoma (PCNSL).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →